Interim NATALEE Data Support Ribociclib Plus Endocrine Therapy for Stage II/III HR-Positive / HER2-Negative Early Breast Cancer

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • 2023 ASCO ANNUAL MEETING – Key Points:
    • NATALEE was designed to evaluate the combination of ribociclib plus endocrine therapy in patients with early breast cancer
    • There was a trend toward improved OS with ribociclib plus endocrine therapy, and a 3-year treatment duration of ribociclib 400 mg showed a predictable safety profile that was more favorable than the 600 mg dose of ribociclib used in the metastatic setting
    • Follow-up data is still being collected, and further quality-of-life results will be provided later in the year
    • The combination of CDK 4 / 6 inhibitor ribociclib plus endocrine therapy significantly improved invasive disease-free survival (iDFS) compared with endocrine therapy alone in a broad population of patients with stage II or III HR-positive /HER2-negative early breast cancer:
      • According to results of the second interim efficacy analysis of the phase 3 NATALEE study
    • With a median follow-up for iDFS of 27.7 months:
      • The risk for invasive disease was reduced by 25.2% with ribociclib plus endocrine therapy compared with endocrine therapy alone (HR 0.748, 95% CI [0.618, 0.906]; P = .0014)
    • The 3-year iDFS rate was 90.4% for the combination therapy compared with 87.1% for endocrine therapy alone:
      • Which is an absolute difference of 3.3%
    • These results support ribociclib plus endocrine therapy as a new and effective treatment of choice for a broad population of at-risk patients with stage II or III HR-positive / HER2-negative early breast cancer, which is easy to identify in clinical practice
#Arrangoiz #BreastSurgeon #MountSinaiMedicalCenter #MSMC #BreastCancer #SurgicalOncologist #CancerSurgeon
Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment